Abeona Therapeutics Inc. $ABEO Shares Purchased by Nan Fung Trinity HK Ltd.

Nan Fung Trinity HK Ltd. increased its holdings in Abeona Therapeutics Inc. (NASDAQ:ABEO) by 336.6% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 552,270 shares of the biopharmaceutical company’s stock after purchasing an additional 425,770 shares during the period. Nan Fung Trinity HK Ltd. owned approximately 0.97% of Abeona Therapeutics worth $2,899,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of ABEO. Royal Bank of Canada lifted its position in Abeona Therapeutics by 49.6% during the first quarter. Royal Bank of Canada now owns 6,500 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 2,155 shares during the last quarter. Dimensional Fund Advisors LP bought a new stake in shares of Abeona Therapeutics in the 1st quarter worth about $154,000. WINTON GROUP Ltd bought a new stake in shares of Abeona Therapeutics in the 2nd quarter worth about $256,000. Rangeley Capital LLC increased its holdings in shares of Abeona Therapeutics by 4.2% in the 1st quarter. Rangeley Capital LLC now owns 60,000 shares of the biopharmaceutical company’s stock worth $269,000 after buying an additional 2,400 shares during the last quarter. Finally, Pale Fire Capital SE raised its position in shares of Abeona Therapeutics by 17.3% during the 2nd quarter. Pale Fire Capital SE now owns 81,945 shares of the biopharmaceutical company’s stock valued at $506,000 after buying an additional 12,100 shares in the last quarter. Hedge funds and other institutional investors own 80.56% of the company’s stock.

Abeona Therapeutics Stock Down 0.4%

ABEO stock opened at $2.29 on Friday. Abeona Therapeutics Inc. has a twelve month low of $2.22 and a twelve month high of $7.65. The stock has a market capitalization of $130.87 million, a price-to-earnings ratio of -2.14 and a beta of 1.50. The firm’s fifty day simple moving average is $4.77 and its two-hundred day simple moving average is $5.40.

Abeona Therapeutics (NASDAQ:ABEO) last released its earnings results on Monday, November 9th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.09. Abeona Therapeutics had a negative net margin of 160.30% and a negative return on equity of 44.82%. The firm had revenue of $13.49 million during the quarter, compared to analyst estimates of $14.82 million. As a group, equities research analysts expect that Abeona Therapeutics Inc. will post -1.00 EPS for the current year.

Insider Buying and Selling

In other Abeona Therapeutics news, Director Mark Alvino sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $5.86, for a total value of $87,900.00. Following the completion of the sale, the director owned 62,065 shares of the company’s stock, valued at $363,700.90. This trade represents a 19.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Madhav Vasanthavada sold 4,902 shares of the firm’s stock in a transaction dated Tuesday, September 29th. The stock was sold at an average price of $5.16, for a total transaction of $25,294.32. Following the completion of the sale, the insider directly owned 285,721 shares of the company’s stock, valued at approximately $1,474,320.36. The trade was a 1.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 55,428 shares of company stock worth $296,508 over the last three months. 7.10% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on ABEO shares. Oppenheimer reaffirmed an “outperform” rating and issued a $21.00 price target (down from $22.00) on shares of Abeona Therapeutics in a report on Friday, August 14th. Wall Street Zen upgraded Abeona Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 1st. Weiss Ratings cut Abeona Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Tuesday. HC Wainwright restated a “buy” rating on shares of Abeona Therapeutics in a research report on Friday, September 25th. Finally, Cantor Fitzgerald raised their price objective on Abeona Therapeutics from $28.00 to $30.00 and gave the company an “overweight” rating in a research note on Friday, September 18th. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $21.00.

Abeona Therapeutics Company Profile

Abeona Therapeutics, Inc. is a biotechnology company focused on developing cell and gene therapies for serious and rare diseases. Its work includes treatments designed to address the underlying genetic causes of disease. The company’s lead product, ZEVASKYN (prademagene zamikeracel), is an autologous gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa, a rare inherited skin disorder. Made from a patient’s skin cells, the therapy uses genetic modification to help cells produce type VII collagen and is applied to wounds.